Growing demand over Relenza

Published: 2009-09-04 06:58:00

Updated: 2009-09-04 06:58:00

Due to growing concerns over the rapidly spreading H1N1 flu virus, many pharmacies are making efforts to secure a sufficient supply of treatment drugs, including GlaxoSmithKline’s antiviral drug Relenza, for their stockpiles.

Industry watchers said the H1N1 flu virus scare will sent the demand...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK